SMT201600291B - Inibitori di proteasi hcv - Google Patents
Inibitori di proteasi hcvInfo
- Publication number
- SMT201600291B SMT201600291B SM201600291T SM201600291T SMT201600291B SM T201600291 B SMT201600291 B SM T201600291B SM 201600291 T SM201600291 T SM 201600291T SM 201600291 T SM201600291 T SM 201600291T SM T201600291 B SMT201600291 B SM T201600291B
- Authority
- SM
- San Marino
- Prior art keywords
- proteasis
- hcv
- inhibitors
- hcv proteasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2009/056937 WO2011034518A1 (en) | 2009-09-15 | 2009-09-15 | Hcv protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201600291B true SMT201600291B (it) | 2016-11-10 |
Family
ID=43758907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201600291T SMT201600291B (it) | 2009-09-15 | 2016-08-29 | Inibitori di proteasi hcv |
Country Status (21)
Country | Link |
---|---|
US (1) | US8389560B2 (it) |
EP (1) | EP2477980B1 (it) |
JP (1) | JP5702388B2 (it) |
KR (1) | KR101670319B1 (it) |
AU (1) | AU2009352688B2 (it) |
CA (1) | CA2774145C (it) |
CY (1) | CY1118136T1 (it) |
DK (1) | DK2477980T3 (it) |
EA (1) | EA022118B1 (it) |
ES (1) | ES2588204T3 (it) |
HR (1) | HRP20161025T1 (it) |
HU (1) | HUE030402T2 (it) |
LT (1) | LT2477980T (it) |
NZ (1) | NZ599133A (it) |
PL (1) | PL2477980T3 (it) |
PT (1) | PT2477980T (it) |
SG (1) | SG179566A1 (it) |
SI (1) | SI2477980T1 (it) |
SM (1) | SMT201600291B (it) |
WO (1) | WO2011034518A1 (it) |
ZA (1) | ZA201202631B (it) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
KR20110075019A (ko) * | 2008-10-15 | 2011-07-05 | 인터뮨, 인크. | 치료용 항바이러스성 펩티드 |
CA2775697A1 (en) * | 2009-09-28 | 2011-03-31 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis c virus replication |
WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN102911254A (zh) * | 2011-08-02 | 2013-02-06 | 上海唐润医药科技有限公司 | Hcv蛋白酶抑制剂 |
CN107964006A (zh) * | 2012-01-11 | 2018-04-27 | 艾伯维公司 | 用于制备hcv蛋白酶抑制剂的方法 |
WO2014044722A1 (en) | 2012-09-20 | 2014-03-27 | Basf Se | Azadibenzofurans for electronic applications |
US20140100364A1 (en) | 2012-10-08 | 2014-04-10 | Abbvie Inc. | Compounds Useful For Making HCV Protease Inhibitors |
PT2909205T (pt) | 2012-10-19 | 2017-02-06 | Bristol Myers Squibb Co | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
CN104557954A (zh) * | 2013-10-16 | 2015-04-29 | 上海唐润医药科技有限公司 | 抗hcv的大环化合物 |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
CN104447952A (zh) * | 2014-12-11 | 2015-03-25 | 上海唐润医药科技有限公司 | 丙肝病毒蛋白酶抑制剂及其合成方法 |
CN108727417B (zh) * | 2015-02-05 | 2021-10-08 | 爱博新药研发(上海)有限公司 | 多环化合物钠盐及其多晶型、制备方法及应用 |
KR102447668B1 (ko) | 2016-06-22 | 2022-09-26 | 이데미쓰 고산 가부시키가이샤 | 유기 발광 다이오드를 위한 특이적으로 치환된 벤조푸로- 및 벤조티에노퀴놀린 |
US10004719B1 (en) * | 2017-05-30 | 2018-06-26 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
CN110958880B (zh) * | 2017-05-30 | 2023-08-08 | 东莞东阳光太景医药研发有限责任公司 | 固体分散制剂 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4555508A (en) | 1984-03-02 | 1985-11-26 | Usv Pharmaceutical Corp. | Antihypertensive spiro-cyclic compounds |
CA2254122A1 (en) | 1996-05-10 | 1997-11-20 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
US5876984A (en) | 1996-09-25 | 1999-03-02 | Shionogi & Co., Ltd | Sequiterpene derivatives having antiviral activity |
BR9712544B1 (pt) | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
WO1999050230A1 (en) | 1998-03-31 | 1999-10-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US20030073618A1 (en) | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
US20020182647A1 (en) | 2001-04-30 | 2002-12-05 | Emmert-Buck Michael R. | Histoscreen method |
NZ530000A (en) | 2001-07-11 | 2007-03-30 | Vertex Pharma | Peptidomimetic bridged bicyclic serine protease inhibitors |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
MXPA04007163A (es) | 2002-01-23 | 2004-10-29 | Schering Corp | Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c. |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
WO2003087092A2 (en) | 2002-04-11 | 2003-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
US7601367B2 (en) | 2002-05-28 | 2009-10-13 | Mirus Bio Llc | Compositions and processes using siRNA, amphipathic compounds and polycations |
MXPA05004670A (es) | 2002-11-01 | 2005-08-18 | Abbott Lab | Agentes anti-infecciones. |
CN1771050A (zh) | 2003-02-07 | 2006-05-10 | 益安药业 | 丙型肝炎丝氨酸蛋白酶的大环抑制剂 |
WO2004092161A1 (en) | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
WO2004092162A1 (en) | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
WO2004094452A2 (en) | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
KR101137572B1 (ko) | 2003-06-11 | 2012-05-30 | 이데라 파마슈티칼즈, 인코포레이티드 | 안정화된 면역조절 올리고뉴클레오티드 |
UY28423A1 (es) | 2003-07-18 | 2005-02-28 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- |
TW200526686A (en) | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
CA2536182C (en) | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
JP4525982B2 (ja) | 2003-09-26 | 2010-08-18 | シェーリング コーポレイション | C型肝炎ウイルスのns3セリンプロテアーゼの大環状インヒビター |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
MXPA06005683A (es) | 2003-11-20 | 2006-12-14 | Schering Corp | Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c. |
TW200518746A (en) | 2003-12-11 | 2005-06-16 | Schering Corp | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
WO2006033878A1 (en) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
US20070207949A1 (en) | 2005-06-02 | 2007-09-06 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
JP2008545748A (ja) | 2005-06-02 | 2008-12-18 | シェーリング コーポレイション | C型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物 |
UY30437A1 (es) | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
WO2008022006A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
WO2008134395A1 (en) * | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis c serine protease inhibitors |
US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
-
2009
- 2009-09-15 LT LTEP09849606.0T patent/LT2477980T/lt unknown
- 2009-09-15 KR KR1020127009259A patent/KR101670319B1/ko active IP Right Grant
- 2009-09-15 SG SG2012018412A patent/SG179566A1/en unknown
- 2009-09-15 DK DK09849606.0T patent/DK2477980T3/en active
- 2009-09-15 EA EA201270423A patent/EA022118B1/ru unknown
- 2009-09-15 CA CA2774145A patent/CA2774145C/en active Active
- 2009-09-15 JP JP2012529723A patent/JP5702388B2/ja not_active Expired - Fee Related
- 2009-09-15 NZ NZ599133A patent/NZ599133A/xx not_active IP Right Cessation
- 2009-09-15 SI SI200931505A patent/SI2477980T1/sl unknown
- 2009-09-15 ES ES09849606.0T patent/ES2588204T3/es active Active
- 2009-09-15 WO PCT/US2009/056937 patent/WO2011034518A1/en active Application Filing
- 2009-09-15 PL PL09849606T patent/PL2477980T3/pl unknown
- 2009-09-15 HU HUE09849606A patent/HUE030402T2/en unknown
- 2009-09-15 US US12/559,818 patent/US8389560B2/en active Active
- 2009-09-15 AU AU2009352688A patent/AU2009352688B2/en not_active Ceased
- 2009-09-15 EP EP09849606.0A patent/EP2477980B1/en active Active
- 2009-09-15 PT PT98496060T patent/PT2477980T/pt unknown
-
2012
- 2012-04-12 ZA ZA2012/02631A patent/ZA201202631B/en unknown
-
2016
- 2016-08-16 HR HRP20161025TT patent/HRP20161025T1/hr unknown
- 2016-08-29 SM SM201600291T patent/SMT201600291B/it unknown
- 2016-08-31 CY CY20161100856T patent/CY1118136T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20110065737A1 (en) | 2011-03-17 |
JP2013504616A (ja) | 2013-02-07 |
ZA201202631B (en) | 2012-12-27 |
EP2477980B1 (en) | 2016-06-08 |
HUE030402T2 (en) | 2017-05-29 |
PT2477980T (pt) | 2016-08-31 |
JP5702388B2 (ja) | 2015-04-15 |
EP2477980A4 (en) | 2013-05-01 |
AU2009352688B2 (en) | 2014-04-17 |
ES2588204T3 (es) | 2016-10-31 |
EP2477980A1 (en) | 2012-07-25 |
CA2774145A1 (en) | 2011-03-24 |
WO2011034518A1 (en) | 2011-03-24 |
CA2774145C (en) | 2015-10-27 |
EA022118B1 (ru) | 2015-11-30 |
DK2477980T3 (en) | 2016-09-12 |
EA201270423A1 (ru) | 2012-09-28 |
KR101670319B1 (ko) | 2016-10-28 |
LT2477980T (lt) | 2016-09-26 |
SI2477980T1 (sl) | 2017-01-31 |
AU2009352688A1 (en) | 2012-04-26 |
KR20120110091A (ko) | 2012-10-09 |
SG179566A1 (en) | 2012-05-30 |
CY1118136T1 (el) | 2017-06-28 |
PL2477980T3 (pl) | 2017-02-28 |
HRP20161025T1 (hr) | 2016-11-04 |
US8389560B2 (en) | 2013-03-05 |
NZ599133A (en) | 2013-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201600291B (it) | Inibitori di proteasi hcv | |
SMT201600075B (it) | Composto di diamminocarbossammide eterociclica | |
DOP2012000114A (es) | Inhibidor bromodominio de benzodiazepina | |
SMT201600104B (it) | Inibitore di bromodominio benzodiazepinico | |
SMT201600267B (it) | Inibitori di syk imidazopirazinici | |
SMT201600311B (it) | Inibitori di cdk | |
SMT201500043B (it) | Indazoli ossazolo-sostituiti come inibitori di pi13-chinasi | |
SMT201500271B (it) | Inibitori di neprilisina | |
CY2015012I2 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
EP2398474A4 (en) | HCV NS5A SHEMMER | |
AP3409A (en) | Inhibitors of flaviviridae viruses | |
EP2575866A4 (en) | HCV NS5A INHIBITORS | |
EP2575475A4 (en) | HCV NS5A INHIBITORS | |
BR112012005438A2 (pt) | inibidores de vírus flaviviridae | |
BR112012005382A2 (pt) | inibidores de jak | |
SMT201600031B (it) | Composti eterociclici di fenossimetile | |
SMT201500268B (it) | Derivato di 5-idrossipirimidin-4-carbossammide | |
SMT201500156B (it) | Composti di diidropirrolonaftiridinione come inibitori di jak | |
UY33155A (es) | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa | |
BRPI1011267A2 (pt) | inibidores de protease | |
DK2506840T3 (da) | Anvendelser af hæmmere af hypoksi-fremkaldende faktorer | |
DK2453858T3 (da) | Fremgangsmåde | |
BR112013010836A2 (pt) | inibidores específicos de ns3 protease de hcv | |
DK2516435T3 (da) | Inhibitorer af AKT-aktivitet | |
IT1400080B1 (it) | Disposizione di esca |